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Twist1 has a well-established role in inducing Epithelial-Mesenchymal Transition (EMT) to promote tumor
invasion and metastasis and can also inhibit apoptosis and confer stemness. In this issue of Cell Stem
Cell, Beck et al. (2015) now show that low levels of Twist1 are essential for tumor initiation, maintenance,
and stemness independent of its EMT-inducing activity.The Twist1 basic helix-loop-helix tran-
scription factor is overrexpressed in
various types of human cancers including
breast, prostate, and gastric cancer and
squamous cell carcinoma (SCC). Mecha-
nistically, numerous cellular functions of
Twist1 have been identified to contribute
to its function in tumor initiation and
progression (Qin et al., 2012). Overex-
pression of Twist1 was first reported to
override Myc-induced apoptosis in tumor
cells (Maestro et al., 1999; Valsesia-Witt-
mann et al., 2004). A number of studies
have shown that Twist1 is a key player
in tumor metastasis by inducing Epithe-
lial-Mesenchymal Transition (EMT) and
promoting invadopodia-mediated extra-
cellular matrix degradation (Yang et al.,
2004; Eckert et al., 2011). Furthermore,
several studies showed that induction of
EMT by Twist1 confers cancer cells with
cancer stem cell properties to promote tu-
mor initiation (Mani et al., 2008). However,
the EMT program predominantly operates
during tumor metastasis, while cancer
stem cell properties are also needed for
tumor initiation. Therefore, it is unclear
whether these two properties func-
tion independently or cooperate during
different stages of tumor progression. In
this issue of Cell Stem Cell, Beck et al.
(2015) report that Twist1 is necessary for
tumor initiation, stemness, and malignant
progression of skin tumor in a dose-
dependent manner (Figure 1). More
importantly, they found that the cancer
stem cell properties induced by Twist1
during tumor initiation are independent
of its role in promoting EMT and tumor
invasion.To understand the role of Twist1 during
different stages of tumor progression, the
authors analyzed Twist1 expression in the
DMBA/TPA carcinogenesis skin tumor
model as well as in the oncogenic KRas-
driven skin tumor mousemodels, in which
individual stages of tumor development,
including tumor initiation, maintenance,
and malignant progression, are well-
defined. Although Twist1 was not ex-
pressed in normal epidermal cells, Twist1
expression was observed in 15% of pap-
illoma and inmore than 50%of SCCs. The
increasing levels of Twist1 expression
in papilloma and SCCs compared to
normal skin suggests that different levels
of Twist1 can differentially contribute
to tumor initiation versus progression. To
address the functional significance of
Twist1 in skin tumor progression, the
authors conditionally deleted one allele
or both alleles of Twist1 in mouse skin
epidermis. Indeed, deletion of one allele
of Twist1 completely blocked the conver-
sion of papilloma to SCC, which is consis-
tent with previous studies showing that
high levels of Twist1 promote EMT and tu-
mor invasion (Yang et al., 2004; Tsai et al.,
2012). Interestingly, homozygous deletion
of Twist1 in both the KRas-driven and the
DMBA/TPA skin tumor model resulted in
inhibition of papilloma development, sug-
gesting that low levels of Twist1 expres-
sion are required for tumor initiation.
To understand how low levels of Twist1
control tumor initiation, Beck et al.
assessed whether Twist1 regulates the
tumor-propagating potential of primary
and malignant skin tumors by serial
dilution and transplantation assays.Cell Stem CelIndeed, Twist1-depleted tumor cells
from papilloma and SCC showed drasti-
cally reduced abilities to form secondary
tumors. Mechanistically, homozygous
deletion of Twist1 reduced cell prolifera-
tion and increased cell death. Interest-
ingly, complete deletion of Twist1 in pap-
illoma cells did not alter the expression
of EMT makers including E-cadherin,
N-cadherin, vimentin, and other EMT-
inducing transcription factors, suggesting
that Twist1 is necessary for conferring
cancer stem cell properties through an
EMT-independent mechanism.
To further understand how Twist1 pro-
motes tumor initiation via inhibiting
apoptosis and promoting proliferation,
the authors show that Twist1 deletion
in papilloma resulted in the increased
expression of p53 target genes specif-
ically involved in cell cycle arrest and
apoptosis, but not genes regulating
senescence. To functionally test whether
p53 mediates Twist1-dependent tumor
initiation ability, the authors ablated both
p53 and Twist1 simultaneously in pre-ex-
isting DMBA/TPA-induced skin tumors.
Surprisingly, although deletion of p53
blocked apoptosis due to a loss of Twist1,
Twist1-induced cell proliferation and sub-
sequent tumor initiation were not rescued,
strongly indicating that Twist1 can modu-
late cell proliferation and tumor stemness
in a p53-independent manner during pap-
illoma initiation.
Previous studies show that several
EMT-inducing factors can promote EMT
and confer cancer stem cell properties
(Mani et al., 2008; Morel et al., 2008),
thus suggesting that the EMT programl 16, January 8, 2015 ª2015 Elsevier Inc. 1
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Figure 1. The Multifunctional Acts of Twist1 during Skin Tumorigenesis
Twist1 expression is induced at a low level during papilloma initiation and further increases in malignant
squamous cell carcinoma (SCC). Differential levels of Twist1 confer distinct cellular functions during mul-
tiple stages of skin tumorigenesis. (1) Low levels of Twist1 prevent p53-induced apoptosis to promote skin
tumor initiation in hyperplasia. (2) Low levels of Twist1 also promote cell proliferation and tumor-initiating
properties in a p53-independent manner in papilloma and Tumor Propagating Cells (TPC). (3) High levels
of Twist1 induce EMT and promote tumor invasion in invasive SCCs.
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linked. Beck et al. show that high levels of
Twist1 promote EMT and invasion. How-
ever, they find that the ability of Twist1
to confer cancer stem cell properties
during tumor initiation is independent of
its role in EMT during tumor invasion. An
upcoming study by Schmidt et al. in Cell
Reports also provides new evidence
on this issue using an inducible Twist1
construct in human mammary epithelial
cells (Schmidt et al., 2015). The authors
found that turning on Twist1 induced
EMT without conferring any mammo-
sphere-forming ability; in contrast, subse-
quently turning off Twist1 led to robust
mammosphere-forming abilities despite
the cells having reverted into an epithe-
lial morphology. Furthermore, the au-
thors showed that transient activation
of Twist1, which is not sufficient to
induce EMT morphological changes,
still promoted mammosphere formation.
Together with the study by Beck et al.,
these studies in both skin and breast cells
indicate that it is not the EMT program per
se that confers cancer stem cell proper-
ties, but additional target genes down-2 Cell Stem Cell 16, January 8, 2015 ª2015 Estream of Twist1. Both studies attempted
to use gene expression profiling to identify
novel Twist1 target genes uniquely asso-
ciated with cancer stem cell properties.
Future functional studies are needed to
understand the action of these target
genes in regulating cancer stem cell prop-
erties induced by Twist1.
Another intriguing question arising from
the Beck et al. study is related to the role
of Twist1 in regulating cell proliferation.
This study shows that low levels of Twist1
are required for cell proliferation and for
p21 suppression during skin tumor initia-
tion in a p53-independent manner. Previ-
ous studies using mouse breast cancer
cell lines have found that knocking down
Twist1 by shRNAs did not affect cell pro-
liferation in culture and tumor growth in
mice (Yang et al., 2004). One plausible
cause for this discrepancy is that certain
cancer cell lines obtain additional muta-
tions to suppress p21 and promote cell
proliferation independent of Twist1, which
was also observed in a small fraction of
papilloma in this study. Using the same
DMBA/TPA skin tumor model, Tsai et al.
show that high levels of Twist1 inductionlsevier Inc.in papilloma can potently induce EMT,
local invasion, SCC conversion, and
dissemination into distant organs. They
also demonstrate that turning off exoge-
nous Twist1 during metastasis coloniza-
tion leads to reversion of EMT and cell
proliferation to generate secondary tu-
mors in distant sites (Tsai et al., 2012).
Together with the current study, these
data suggest that low levels of Twist1
are required for tumor cell proliferation
and tumor stemness through a yet un-
known mechanism, whereas high levels
of Twist1 switch cells into a migratory
mode with reduced proliferation to
promote metastasis. Detailed analyses
on how differential levels of Twist1 regu-
late distinct transcription machineries to
drive target genes responsible for cell
proliferation versus cell migration will
provide crucial mechanistic insights on
the multiple functions of Twist1 during
tumorigenesis.REFERENCES
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